Where: Largo, Florida
Details: PharmaLink is expanding its flagship operations center by more than 50,000 square feet, bringing the total facility size to 150,000 square feet. The expansion, set to open in June 2025, will more than double the company's processing capacity and support onboarding of additional manufacturers, chain pharmacies, and wholesale clients. The new space will make room for a suite of advanced robotic systems and proprietary workflow software launching in November 2025. These upgrades aim to boost throughput, shorten client cycle times, enhance compliance, and support sustainability goals. The project will also create dozens of skilled jobs in operations, IT, and quality assurance. Who: NOVA Chemicals, with support from the Plastics Industry Association (PLASTICS)
Where: Connersville, Indiana
© Plastics Industry Association (PLASTICS) | NOVA
Matt Seaholm, PLASTICS President and CEO, and Andy Brewer, PLASTICS Director of Sustainability & Recycling, at SYNDIGO1 in Connersville, Indiana. Details:  NOVA Chemicals has officially opened its first-ever mechanical recycling facility , SYNDIGO1, which is among the world’s largest polyethylene film recycling plants. Located in Connersville, Indiana, the plant will be fully operational by the end of 2025 and is expected to process 145,000 bales of plastic film annually, producing approximately 110 million pounds of recycled polyethylene by 2026. The $519 billion U.S. plastics industry marked the facility's opening with a celebration attended by PLASTICS President and CEO Matt Seaholm. The plant supports roughly 125 jobs and is certified by both the FDA and GreenBlue for producing 100% post-consumer recycled polyethylene. SYNDIGO1 will partner with major retailers and distribution centers to collect and reprocess film into high-quality resin for packaging applications. Who: AbbVie, a global biopharmaceutical company
Where: North Chicago, Illinois
Details: AbbVie is investing $195 million to expand its North Chicago manufacturing plant , boosting U.S. production of active pharmaceutical ingredients (APIs) used in neuroscience, immunology, and oncology medicines. The project is part of the company's broader plan to invest more than $10 billion in domestic facilities over the next decade, strengthening innovation and manufacturing capabilities in critical therapeutic areas. Construction on the new facility will begin in fall 2025, with full operations expected in 2027. The expansion will increase AbbVie's chemical synthesis capacity and add to its existing U.S. manufacturing network, which already supports over 6,000 jobs across 11 sites. Headquartered in Illinois with more than 11,000 employees in the state, AbbVie says the investment underscores its long-term commitment to domestic production, job creation, and advancing next-generation treatments. Who: Guill Tool, a global leader in extrusion tooling
Where: West Warwick, Rhode Island (Guill headquarters)
© Guill Tool
Fluidized bath in the test extrusion facility. Details: Guill Tool has expanded its capabilities with the creation of Guill Labs , combining a state-of-the-art rheology lab with a dedicated extrusion testing facility to better serve the global extrusion market. The rheology lab analyzes the flow behavior of plastics and rubber, helping customers predict how materials will perform in Guill's extrusion dies before production. Using equipment such as a rotational rheometer, scanning calorimeter, thermal conductivity meter, and a new CT scanner, the lab generates precise data to optimize tooling geometry and simulate real-world conditions. The new extrusion test lab houses two Killion 1.25-in extruders, a vacuum tank, dual-axis laser gauge, drying systems, a custom tubing puller, and an Accurate Thermal Systems fluidized bath with a 122 to 1121°F (50 to 605°C) range. The facility supports single and co-extrusion trials, rotary die extrusion, and testing with exotic materials. In addition to materials and die testing, Guill Labs offers extrusion training, die cleaning, sample inspection, and end-product testing—enabling customers to validate materials, dies, and actual run times onsite for faster, higher-quality production.

New U.S. Manufacturing Facilities From AbbVie, NOVA Chemicals, Guill Tool, and More

July 21st, 2025
July 21, 2025
Largo, Florida and Boston, Massachusetts – PharmaLink, a leading pharmaceutical reverse logistics platform, announced today that it has received a growth investment from WestView Capital Partners, a Boston-based growth equity firm focused on middle market growth companies. Headquartered in Largo, Florida, PharmaLink is a leading pharmaceutical reverse logistics platform, serving as a centralized hub for the processing of unsaleable, expired, and recalled pharmaceutical products. Leveraging its unique position within the healthcare supply chain, PharmaLink supports pharmacies, hospitals, wholesalers, and manufacturers in efficiently managing product returns and refunds while ensuring full compliance with federal and state regulations. Its comprehensive suite of services includes product pickup and shipping, return and recall processing, credit reporting, reconciliation, regulatory documentation, and environmentally compliant disposal. PharmaLink’s intuitive user interface is backed by a powerful infrastructure that drives accurate processing and delivers real-time data with actionable analytics. In May, the Company announced a 50,000-square-foot expansion of its flagship operations center, more than doubling its processing capacity to meet rising demand across the pharmaceutical supply chain. This expanded footprint will pave the way for cutting-edge automation going live later this year – driving greater compliance, efficiency, and sustainability while ensuring scalable capacity for continued growth. “Our partnership with WestView marks an exciting step forward for PharmaLink as we continue to deliver premium reverse logistics solutions to our clients,” said Thierry Beckers, President & CEO of PharmaLink. “We’ve consistently invested back into PharmaLink to scale our operations and meet the evolving needs of our customers. We selected WestView because we believe they share our long-term vision and bring the strategic insight and partnership needed to help guide our next phase of growth.”
“We’re thrilled to be partnering with Thierry, Adam Bottie (SVP of Strategic Development & Revenue), and the rest of the fantastic team at PharmaLink to support the continued expansion and enhancement of their service capabilities,” said Jeff Clark, Principal at WestView Capital Partners. “PharmaLink represents a great combination of WestView’s experience in both pharma services and distribution / logistics companies.”
Added Tom Gilligan, Vice President at WestView, “As the leading independent reverse logistics platform, PharmaLink has achieved impressive growth by delivering critical services to key constituents across the healthcare supply chain. We look forward to being part of their next chapter.”
PharmaLink was advised by Raymond James and represented by Johnson, Pope, Bokor, Ruppel & Burns, LLP, while WestView was represented by Latham & Watkins LLP. PharmaLink is WestView's tenth investment from WestView's Fund V, which it started investing in June 2023. About PharmaLink
PharmaLink is the premier pharmaceutical reverse distributor, serving as a centralized hub for the processing of unsaleable pharmaceutical products. With services spanning the complete spectrum of the pharmaceutical supply chain, PharmaLink has a 360-degree view of the needs of all businesses involved in the delivery of healthcare. With customizable solutions available for any size client, PharmaLink is the choice provider for pharmaceutical return, recall, and disposal solutions for dispensers, wholesalers and manufacturers. For more information, please visit pharmalinkinc.com. About WestView Capital Partners
WestView Capital Partners, a Boston-based growth equity firm focused exclusively on middle market growth companies, manages $2.7 billion in capital across five funds. WestView partners with existing management teams to sponsor minority and majority recapitalizations, growth, and consolidation transactions in several sectors, including healthcare technology and outsourcing, business services, software and IT services, and growth industrial. For more information, please visit wvcapital.co m .

PharmaLink Welcomes Growth Investment from WestView Capital Partners

European Business & Finance Magazine
May 30, 2025
1
LARGO, FL / ACCESS Newswire / May 30, 2025 / PharmaLink, a leader in pharmaceutical reverse distribution and returns management, today unveiled plans for a more than 50,000-square-foot expansion of its flagship operations center that will bring the overall total square footage of the facility to 150,000 square feet. The new space, scheduled to open in June 2025, will more than double PharmaLink’s processing capacity, positioning the company to onboard additional manufacturer, chain pharmacy, and wholesale clients while continuing to deliver world-class service to the entire pharmaceutical supply chain. “Demand for efficient and compliant returns and recall solutions has never been higher,” said Thierry Beckers, CEO of PharmaLink. “By investing in this new facility and state-of-the-art automation, we’re ensuring our partners that we have the scale and technology they need to navigate an increasingly complex reverse distribution process today and for years to come.”
Best-in-Class Automation Coming November 2025
The expansion makes room for a suite of advanced robotic systems and proprietary workflow software that will go live in November 2025. These innovations are designed to:
Boost throughput and accuracy by automating high-volume sortation, scanning, and data capture tasks. Shorten client cycle times-accelerating credit reconciliation and product disposition. Enhance compliance & transparency with enhanced tracking and reporting. Support sustainability goals by optimizing processing and reducing waste. “Our new automation platform isn’t just about speed, it’s about smarter, safer handling of every unit that passes through our doors,” added Ray Bodamer, Vice President, Operations. “That translates directly into bulletproof compliance and increased quality for our customers.”
Expanding Value Across the Supply Chain
PharmaLink’s enlarged footprint and technology upgrades will allow the company to:
Process millions more product units annually, ensuring ample capacity to support large customers in all classes of trade and recall events. Create dozens of skilled jobs in operations, IT, and quality assurance at the Largo, FL campus. About PharmaLink
PharmaLink is a leading provider of pharmaceutical reverse distribution, product recall, and returns credit management services. Trusted by manufacturers, wholesale distributors, and major pharmacies in various classes of trade, PharmaLink combines deep regulatory expertise with innovative technology to maximize inventory performance, ensure compliance, and protect public health. Contact Information:

PharmaLink Announces Facility Expansion to Double Capacity and Support Automation

Press Release• May 30, 2025 13:00 EDT
LARGO, Fla., May 30, 2025 (Newswire.com)        - PharmaLink, a leader in pharmaceutical reverse distribution and returns management, today unveiled plans for a more than 50,000-square-foot expansion of its flagship operations center that will bring the overall total square footage of the facility to 150,000 square feet. The new space, scheduled to open in June 2025, will more than double PharmaLink's processing capacity, positioning the company to onboard additional manufacturer, chain pharmacy, and wholesale clients while continuing to deliver world-class service to the entire pharmaceutical supply chain. "Demand for efficient and compliant returns and recall solutions has never been higher," said Thierry Beckers, CEO of PharmaLink. "By investing in this new facility and state-of-the-art automation, we're ensuring our partners that we have the scale and technology they need to navigate an increasingly complex reverse distribution process today and for years to come." Best-in-Class Automation Coming November 2025
The expansion makes room for a suite of advanced robotic systems and proprietary workflow software that will go live in November 2025. These innovations are designed to:
Boost throughput and accuracy by automating high-volume sortation, scanning, and data capture tasks. Shorten client cycle times-accelerating credit reconciliation and product disposition. Enhance compliance & transparency with enhanced tracking and reporting. Support sustainability goals by optimizing processing and reducing waste. "Our new automation platform isn't just about speed, it's about smarter, safer handling of every unit that passes through our doors," added Ray Bodamer, Vice President, Operations. "That translates directly into bulletproof compliance and increased quality for our customers." Expanding Value Across the Supply Chain
PharmaLink's enlarged footprint and technology upgrades will allow the company to:
Process millions more product units annually, ensuring ample capacity to support large customers in all classes of trade and recall events. Create dozens of skilled jobs in operations, IT, and quality assurance at the Largo, FL campus. About PharmaLink
PharmaLink is a leading provider of pharmaceutical reverse distribution, product recall, and returns credit management services. Trusted by manufacturers, wholesale distributors, and major pharmacies in various classes of trade, PharmaLink combines deep regulatory expertise with innovative technology to maximize inventory performance, ensure compliance, and protect public health. Contact Information:

PharmaLink Announces Facility Expansion to Double Capacity and Support Automation
LARGO, FL / ACCESS Newswire / May 30, 2025 / PharmaLink, a leader in pharmaceutical reverse distribution and returns management, today unveiled plans for a more than 50,000-square-foot expansion of its flagship operations center that will bring the overall total square footage of the facility to 150,000 square feet. The new space, scheduled to open in June 2025, will more than double PharmaLink's processing capacity, positioning the company to onboard additional manufacturer, chain pharmacy, and wholesale clients while continuing to deliver world-class service to the entire pharmaceutical supply chain. "Demand for efficient and compliant returns and recall solutions has never been higher," said Thierry Beckers, CEO of PharmaLink. "By investing in this new facility and state-of-the-art automation, we're ensuring our partners that we have the scale and technology they need to navigate an increasingly complex reverse distribution process today and for years to come." Best-in-Class Automation Coming November 2025
The expansion makes room for a suite of advanced robotic systems and proprietary workflow software that will go live in November 2025. These innovations are designed to:
Boost throughput and accuracy by automating high-volume sortation, scanning, and data capture tasks. Shorten client cycle times-accelerating credit reconciliation and product disposition. Enhance compliance & transparency with enhanced tracking and reporting. Support sustainability goals by optimizing processing and reducing waste. "Our new automation platform isn't just about speed, it's about smarter, safer handling of every unit that passes through our doors," added Ray Bodamer, Vice President, Operations. "That translates directly into bulletproof compliance and increased quality for our customers." Expanding Value Across the Supply Chain
PharmaLink's enlarged footprint and technology upgrades will allow the company to:
Process millions more product units annually, ensuring ample capacity to support large customers in all classes of trade and recall events. Create dozens of skilled jobs in operations, IT, and quality assurance at the Largo, FL campus. About PharmaLink
PharmaLink is a leading provider of pharmaceutical reverse distribution, product recall, and returns credit management services. Trusted by manufacturers, wholesale distributors, and major pharmacies in various classes of trade, PharmaLink combines deep regulatory expertise with innovative technology to maximize inventory performance, ensure compliance, and protect public health. Contact Information:

EQL Pharma is a pharmaceutical company with a focus on developing and distributing pharmaceutical products. The company specializes in offering generic drugs and specialty pharma products that cater to various health needs. Its products are designed to be equivalent to brand-name drugs but are typically sold at lower prices. It was founded in 2006 and is based in Lund, Sweden.

EQL Pharma

EQL Pharma AB has entered into an exclusive distribution agreement with Pharmalink for its product Mellozzan for the GCC region comprising of United Arab Emirates , Saudi Arabia , Kuwait , Qatar , Oman and Bahrain .

EQL Pharma signs a distribution agreement with a large distributor in the GCC countries for Mellozzan (melatonin)

CANNORDIC A/S is a MedTech company involved in the development and commercialization of cannabinoid-based medical devices. The company provides topical treatments that are intended for managing pain and autoimmune conditions. CANNORDIC's products are registered as medical devices containing cannabidiol and adhere to regulations in various countries including Europe and the US. It was founded in 2011 and is based in Copenhagen, Denmark.

CANNORDIC

TraceLin focuses on supply chain orchestration and digitalization within the healthcare and life sciences sectors. The company provides the Opus Platform, a suite of multi-enterprise applications designed for supply chain processes and industry intelligence. It was founded in 2009 and is based in North Reading, Massachusetts.

TraceLink

Amgen operates as a biotechnology company. It uses living cells to create biologic medicines. The company develops and manufactures therapeutics for the treatment of serious illnesses, including cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases. Amgen's products are intended to address diseases with limited treatment options. Amgen was formerly known as Applied Molecular Genetics. It was founded in 1980 and is based in Thousand Oaks, California.

Amgen

Harte Hanks

Private Equity

PharmaLink is a pharmaceutical reverse distribution provider in the healthcare sector. The company offers services that encompass the entire pharmaceutical supply chain, focusing on the return processing of nonsalable products and their safe removal from the marketplace. PharmaLink caters to businesses involved in healthcare delivery, providing solutions that ensure compliance with regulatory standards. It was founded in 2000 and is based in Largo, Florida.

Date	7/21/2025
Round	Private Equity
Amount
Investors	WestView Capital Partners
Valuation	$XXM
Revenue	0 FY undefined
Sources	1

First funding	7/21/2025
Last Funding	7/21/2025
Investor	WestView Capital Partners
Rounds	1 Private Equity
Board Seats
Type	Private Equity
Location	Massachusetts

Date	6/12/2023
Investment Stage
Companies	PharmaReturns
Valuation	$XXM
Total Funding
Note	Acquired
Sources	1

How VCs Use CB Insights

Professional Services

Platform Overview

PharmaLink

Investors Count

Funding, Valuation & Revenue

PharmaLink Investors

PharmaLink Acquisitions

1 Acquisition